In fiscal 2025, which ended Dec 31, 2025, Bionano Genomics, Inc. used $16.3 million of cash from operations, up 76.3% from the year before.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jun 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
FY 2018
Dec 31, 2018
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
9
-27.4%
|
10
-32.1%
|
14
+2.3%
|
14
+42.5%
|
10
+187.1%
|
3
+126.6%
|
1
+31.1%
|
1
-14.6%
|
1
|
| Stock-based compensation |
4
-48.5%
|
5
-53.4%
|
10
-35.9%
|
15
-32.3%
|
22
+130.7%
|
10
+525.4%
|
2
+15.5%
|
1
+12.7%
|
1
|
| Operating cash flow |
-20
+21.4%
|
-16
+76.3%
|
-69
+44.9%
|
-125
-0.3%
|
-125
-73.5%
|
-72
-87.7%
|
-38
-29.7%
|
-30
-48.1%
|
-20
|
| Investing | |||||||||
| Capital expenditures |
—
|
—
|
—
|
—
|
—
|
—
|
0
-100.0%
|
0
-81.6%
|
0
|
| Investing cash flow |
18
+227.7%
|
-13
-117.3%
|
74
+205.7%
|
24
-70.8%
|
83
+129.8%
|
-278
-11249.5%
|
-2
-3912.7%
|
-0
+81.6%
|
-0
|
| Financing | |||||||||
| Financing cash flow |
3
-88.1%
|
24
+275.7%
|
-14
-112.0%
|
114
+394.7%
|
23
-93.2%
|
336
+443.0%
|
62
+103.8%
|
30
-15.1%
|
36
|
| Change in cash | |||||||||
| Effect of exchange rate |
0
+315.4%
|
-0
-57.1%
|
-0
-110.8%
|
0
+271.1%
|
-0
|
—
|
—
|
—
|
—
|
| Net change in cash |
1
+103.7%
|
-5
+42.3%
|
-9
-168.3%
|
13
+167.4%
|
-19
-37.5%
|
-14
-165.7%
|
21
+2580.3%
|
1
-94.9%
|
16
|
| Free cash flow |
—
|
—
|
—
|
—
|
—
|
—
|
-38
-29.5%
|
-30
-45.9%
|
-20
|
| Ratios | |||||||||
| Free cash flow margin |
—
|
—
|
—
|
—
|
—
|
—
|
-450.59%
|
-292.12%
|
-168.95%
|
| Capital expenditures to revenue |
—
|
—
|
—
|
—
|
—
|
—
|
0.00%
|
0.60%
|
2.76%
|
| Stock-based compensation to revenue |
11.62%
|
15.90%
|
31.64%
|
42.03%
|
80.63%
|
54.05%
|
18.28%
|
13.29%
|
9.95%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BNGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411690
- Former names
- BioNano Genomics, Inc (until Oct 20, 2021); Bionano Genomics, Inc (until Oct 20, 2021); BioNanomatrix Inc (until Mar 24, 2011)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Source: SEC EDGAR filings. This is company-reported data, not investment advice.